COMMUNIQUÉS West-GlobeNewswire

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
28/02/2025
Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in [...]
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
28/02/2025
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
28/02/2025
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 -- -- [...]
Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call
28/02/2025
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from the U.S. Food and [...]
RadNet Reports Fourth Quarter 2024 Results, Including Record Revenue and Adjusted EBITDA(1) and Releases 2025 Financial Guidance
27/02/2025
Total Company Revenue increased 13.5% to a quarterly record of $477.1 million in the fourth quarter of 2024 from $420.4 million in the fourth quarter of 2023; Revenue from the Digital Health reportable segment ( [...]
Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany
27/02/2025
Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development. LEXINGTON, [...]
Anaptys Announces Participation in March Investor Conferences
27/02/2025
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
27/02/2025
SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi , a telehealth [...]
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
27/02/2025
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data [...]
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
27/02/2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to [...]
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
27/02/2025
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - [...]
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
27/02/2025
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended [...]
GENFIT Announces Revenues and Cash Position as of December 31, 2024
27/02/2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024 Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen’s Iqirvo® (elafibranor) [...]
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2024
27/02/2025
Trésorerie et équivalents de trésorerie : 81,8 millions d’euros au 31 décembre 2024 Chiffre d’affaires : 67,0 millions d’euros au 31 décembre 2024, dont 48,7 millions d'euros de paiement d'étape lors de la première [...]
Pennant Reports Fourth Quarter and Fiscal Year 2024 Results
27/02/2025
Conference Call and Webcast scheduled for tomorrow, February 28, 2025 at 10:00 am MT EAGLE, Idaho, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
LeMaitre Q4 2024 Financial Results
27/02/2025
BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+ [...]
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
27/02/2025
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results
27/02/2025
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
27/02/2025
- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer (“mCRC”) clinical trial (CRDF-004) - - Priced oversubscribed $40 million underwritten registered [...]

Pages